Q2
COYA — Q2 2026 Financial Report Analysis
Coya's Q2 2026 net loss widened 8.9% to $6.6 million as spending on its COYA 302 ALS trial rose; $43.2 million in cash is guided to last into the second half of 2027, past the trial's topline readout expected in early Q2 2027.